By Colin Kellaher
Clinical-stage biotechnology company Galecto is scrapping its lead product candidate following the failure of a Phase 2b study in the chronic lung disease idiopathic pulmonary fibrosis, or IPF.
The Boston company on Tuesday said the study evaluating the safety and efficacy of inhaled GB0139 for the treatment of IPF missed…
Read the full article here
European companies that have added a US listing often do not see…
Young Americans’ confidence in the apparatus of government has dropped dramatically to…
Unlock the White House Watch newsletter for freeYour guide to what the…
Investors are turning to sanctions-proof bets on Russian bonds and the rouble…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…
